ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1379	National Cancer Institute	Html	en	Cervical Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may increase the risk of developing cervical cancer and about approaches that may help in the prevention of this disease.	normal cervical cytology 0.510493 vaccine-treated women 0.487201 HPV types 0.757372 vaccine efficacy 0.741841 9-valent VLP vaccine 0.591937 vaccine-related HPV types 0.575946 prophylactic HPV vaccine 0.687205 HPV DNA testing 0.579437 vaccine efficacy rate 0.600644 persistent infection 0.526745 VLP vaccine 0.652393 HPV titers 0.562213 L1/2 HPV vaccines 0.566712 HPV type vs 0.562578 HPV-16/HPV-18 VLP vaccine 0.605344 pre-existing HPV infection 0.589015 cervical HPV DNA 0.601237 cervical cancers 0.492563 HPV-16/18 vaccine 0.555263 cervical cancer 0.587492 Rica Vaccine Trial 0.588987 nonvalent HPV vaccine. 0.569038 persistent HPV 0.541143 L1 VLP vaccine 0.61267	oncogenic HPV types 0.60386 two-dose schedule 0.501418 women 0.610755 9-valent HPV vaccine 0.681373 study 0.489719 HPV vaccination 0.541014 fully vaccinated women 0.493555 similar vaccine efficacy 0.608995 qHPV vaccine 0.557165 HPV vaccine 0.814126 true vaccine efficacy 0.62572 new vaccine 0.558251 12-month persistent infection 0.491511 invasive cervical cancer 0.57017 HPV infection offer 0.625011 common HPV types 0.578468 Vaccine efficacy rates 0.60682 9vHPV vaccine group 0.59158 bivalent HPV vaccine 0.686822 HPV infection 0.632752 vaccine 0.940033 placebo-controlled trial 0.490062 international randomized trial 0.490281 oncogenic types 0.491299	CLICK HERE
1394	National Cancer Institute	Html	en	Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors).	patient selection factors 0.438228 tumor cell types 0.413939 functional tumors 0.556939 slow-growing tumors 0.428195 pituitary tumors 0.418826 functional pancreatic neuroendocrine 0.426256 islet cell tumors 0.811481 preoperative dual-phase thin-section 0.348132 bone metastases 0.398217 islet cell cancers 0.399777 distinctive metabolic effects 0.341484 secondary endocrine tumors 0.452606 liver metastases 0.990586 unresectable liver metastases 0.497768 endocrine pancreas glands 0.386 metastatic disease 0.427564 sporadic islet cell 0.397131 resectable liver metastases 0.506505 venous sampling 0.390094 surgical resection series 0.389796 visible liver metastases 0.615044 liver neuroendocrine metastases 0.512043 individual tumors 0.388972 progressive pancreatic NETs 0.411807 clinical manifestations 0.349816	percutaneous alcohol ablation 0.339566 antihormonal pharmacologic therapy 0.339279 conventional imaging techniques 0.33881 radiofrequency ablation 0.342021 pancreatic resection 0.466639 pancreatic islets 0.36916 ulcer-producing Zollinger-Ellison syndrome 0.354188 somatostatin-receptor scintigraphy 0.356211 slow-growing metastatic islet 0.423125 pancreatic NETs 0.575547 technically demanding tests 0.350314 multiple endocrine neoplasia 0.362304 retrospective case series 0.340498 hormonally functional tumors 0.47568 tumor suppressor gene 0.392672 pancreatic islet cell 0.465855 overall tumor burden 0.363718 grossly visible liver 0.505977 MEN-1 syndrome 0.346786 pancreatic neuroendocrine tumors 0.701933 liver resection 0.37949 arterial stimulation 0.345171 common exocrine adenocarcinomas 0.348715 preoperative localization studies 0.4603	CLICK HERE
1507	National Cancer Institute	Html	en	Extragonadal Germ Cell Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of extragonadal germ cell tumors.	residual mass 0.384023 large tumor volume 0.30085 residual disease. 0.273583 recurrent testicular cancer. 0.3175 cisplatin-based chemotherapy regimens 0.371374 PDQ cancer information 0.391809 bulky tumors 0.328858 nonseminoma germ cell 0.421124 cell tumors. 0.272309 nonseminomatous germ cell 0.40313 clinical trials 0.311324 relatively small tumors 0.373793 germ cells 0.335003 particularly young individuals 0.307507 Initial chemotherapy 0.290755 cancer information summary 0.37005 breast cancer prevention 0.298248 careful testicular examination 0.334354 Initial debulking surgery 0.299396 extragonadal primary tumors 0.367991 patients 0.377174 BEP regimen 0.273424 NCI’s PDQ 0.288373 PDQ Adult Treatment 0.321273	NCI PDQ cancer 0.337916 Craniospinal radiation therapy 0.306681 extragonadal germ cell 0.679693 international germ cell 0.403901 tumor prognostic classification 0.317369 overall survival rates 0.302813 long-term disease-free survival 0.296962 chemotherapy course 0.295979 major clinical trial 0.309884 autologous bone marrow 0.294582 advanced disseminated germ 0.372421 seminomatous germ cell 0.403127 nonseminomatous extragonadal germ 0.370944 testicular seminoma 0.333059 serum alpha fetoprotein 0.309001 high-risk patients 0.281542 larger residual masses 0.321492 National Cancer Institute 0.298826 PDQ documents 0.279503 nonseminoma testicular cancer 0.332786 nonlocalized tumors 0.326576 germ cell tumors 0.92252 residual mass posttreatment 0.32699 Hematologic toxic effects 0.298226	CLICK HERE
1655	National Cancer Institute	Html	en	Antineoplastons (PDQ®)–Patient Version	Expert-reviewed information summary about antineoplastons as a treatment for people with cancer.	treatment 0.589875 cancer treatment 0.543159 cancer prevention 0.485229 Complementary Therapies Editorial 0.5308 certain cancer cells 0.51088 ongoing clinical trials 0.486889 human cancer cells 0.5323 Drug Administration 0.502832 Cancer Information Specialist 0.500618 cancer cells 0.568381 Cancer Information Service 0.566613 Dr. Burzynski permission 0.49482 PDQ cancer information 0.62364 Cancer Complementary 0.511148 CAM therapies 0.485534 non-randomized clinical trials 0.489986 treatment clinical trials 0.501989 National Cancer Institute 0.756717 clinical trials 0.926048 alternative medicine 0.557845 health care 0.482491 cancer information summary 0.569724 antineoplaston therapy 0.555366 alternative cancer therapies 0.505402	Federal Trade Commission 0.489849 National Institutes 0.483064 clinical trial 0.5421 new treatment 0.570175 CAM cancer research 0.494036 breast cancer prevention 0.482874 PDQ health 0.499386 cancer patients 0.558509 Cancer Care page 0.48497 S. R. Burzynski 0.50185 PDQ summary 0.490596 antineoplastons 0.689146 liver cancer cells 0.500913 Dr. Burzynski 0.778336 NCI PDQ cancer 0.539329 cancer information database 0.507025 cancer clinical trials 0.525243 colon cancer cells 0.502046 alternative therapies 0.539961 cancer information summaries 0.507383 possible cancer treatment 0.520373 Therapies Editorial Board 0.510662 cancer 0.84723	CLICK HERE
1732	National Cancer Institute	Html	en	Targeted Cancer Therapies	A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival.	targeted therapies 0.916839 traditional chemotherapy drugs 0.434184 cancer vaccines 0.439223 cancer cells 0.924402 new blood vessel 0.443884 leukemic cells 0.432134 angiogenesis inhibitors 0.440608 Targeted cancer therapies 0.81804 fact sheets Cancer 0.457828 cancer cell growth 0.589511 specific cancer cells 0.553642 gene expression modulators 0.438407 pancreatic cancer 0.4493 hormone therapies 0.533362 specific target protein 0.46382 differentially expressed target 0.440917 nci-supported clinical trials 0.437017 molecularly targeted drugs 0.562455 clinical trials 0.591045 tumor cells 0.46028 normal cells 0.520102 targeted therapy 0.645434 specific targeted therapy 0.552585 breast cancer 0.484727	Biological Therapies 0.463149 growth factor receptor 0.473185 cancerous cells 0.44351 cancer development 0.434952 experimental targeted therapies 0.619071 targeted therapy trastuzumab 0.545984 Keytruda®) 0.487223 specific types 0.440167 prostate cancer 0.45274 cancer clinical trials 0.499699 tumor cell proliferation 0.433817 certain cancer types 0.465459 high blood pressure 0.438907 metastatic breast cancer 0.450488 particular targeted therapy 0.540161 epidermal growth factor 0.475814 specific molecular targets 0.438616 signal transduction inhibitors 0.526574 potential targets 0.462585 certain immune cells 0.461941 (Rituxan Hycela™) 0.432805 different targeted therapies 0.660128 monoclonal antibodies 0.565531	CLICK HERE
1985	National Cancer Institute	Html	es	Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de tumores de encéfalo infantiles.	espinal infantiles.ampliar punción 0.671368 Organización Mundial 0.330213 células madre 0.838888 efectos secundarios meses 0.514746 siguientes aspectos 0.364078 vía oral 0.337627 encéfalo benignos 0.752955 PDQ Descripción 0.372391 efectos tardíos 0.660507 PDQ correspondiente 0.464116 tumor subtipo 0.432726 PDQ Efectos tardíos 0.450037 cáncer.ampliar aspiración 0.351047 Astrocitoma pilomixoide 0.336263 líquido cefalorraquídeo 0.817195 National Cancer Institute 0.340319 siguientes riesgos 0.328861	Instituto Nacional 0.370517 PDQ Tratamiento 0.975349 riesgo promedio 0.357023 presente sección 0.332468 siguientes signos 0.392336 nuevos tipos 0.34964 siguientes factores 0.362333 sistema nervioso central 0.653419 Physician Data Query 0.447911 gliomas astroblastoma 0.333341 pdq correspondiente tipo 0.412457 alto astrocitoma 0.3322 panel derecho 0.358602 espinal infantiles recién 0.572263 siguientes pruebas 0.390652 siguientes sumarios 0.353304 siguientes trastornos 0.347907	CLICK HERE
3419	National Cancer Institute	Html	es	Accidentes en plantas nucleares de electricidad y el riesgo de cáncer	Hoja informativa acerca de los riesgos del cáncer asociados con accidentes en plantas nucleares de electricidad. Incluye información para pacientes con cáncer que viven en una zona que puede haber sido afectada por un accidente en una planta nuclear.	Atomic Radiation 0.316837 United Nations 0.364483 accident―An epidemiological perspective 0.318721 Zablotska L 0.256274 assembly with scientific 0.304698 Chernobyl-related thyroid 0.281728 Nations Scientific Committee 0.309452 Ulanovsky AV 0.266554 case-control study 0.27312 Brenner AV 0.261036 altas dosis 0.502454 Health effects 0.274048 Cardis E 0.255707 Hatch M 0.715405 Instituto Nacional 0.562168 consecuente exposición 0.36176 related disorders among 0.314284 Chernobyl nuclear power 0.336354 causa cáncer 0.40919 Life Span Study 0.319261 Mykola DT 0.263715 Environmental Health Perspectives 0.308221 PubMed Abstract 0.845077 Finch SC 0.258873 Clinical Oncology 0.262917	Bouville A 0.255535 Chernobyl disaster 0.278477 Annex D 0.255425 Epidemiologic Reviews 0.264619 Amenaza Radiológica 0.258735 Individual thyroid 0.27723 workers from ukraine 0.329042 inhalar partículas 0.413261 Drozdovitch VV 0.265349 Ukraine related 0.277279 Ukranian-American study 0.271859 Contributions from long-lived 0.322355 quimioterapia sistémica 0.267728 Ionizing Radiation 0.316029 incident thyroid cancers 0.332215 Health Physics 0.266767 Chornobyl accident 0.268808 Ciencias Demográficas 0.257571 Belarus—part II 0.255864 thyroid cancers 0.38621 manejo médico 0.356172 medio ambiente 0.973732 Minenko VF 0.264858 Segunda Guerra Mundial 0.28983	CLICK HERE
15908	National Cancer Institute	Html	es	Laetrilo (amigdalina) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer.	Natl Acad Sci 0.351583 institute's retrospective laetrile 0.328712 treated with laetrile 0.349302 Exp Med Surg 0.328157 Promoting poison 0.33939 antitumor activity 0.465434 cases treated with 0.28668 treatment with laetrile 0.295229 with laetrile 0.90547 CA Cancer 0.770829 Acta Unio Int 0.423146 Cancer Industry 0.474642 Med Hypotheses 0.298922 Cancer Commission 0.379224 Estados Unidos 0.752083 Amygdalin induces apoptosis 0.284053 Navarro MD 0.430756 Unio Int Contr 0.427919 Five years 0.324596 Ellison NM 0.316229 Bickis IJ 0.282987 Acad Med 0.304051 Ames MM 0.502122 Laetrile toxicity studies 0.333014 Med Assoc 0.356472	Diss Abstr Int 0.346583 years experience with 0.456942 Proc Natl Acad 0.355643 vía oral 0.317497 Laetrile toxicity 0.342269 retrospective laetrile analysis 0.331541 Cancer Establishment 0.478533 experience with laetrile 0.549066 Dorr RT 0.337868 Cancer Institute retrospective 0.411789 Unproven methods 0.542254 Treat Rep 0.798281 current status 0.343299 Intern Med 0.566133 Kovach JS 0.535271 with laetrile therapy 0.559394 Clin Nutr 0.378962 Int Contr Cancrum 0.427916 laetrile intoxication 0.281414 Moertel CG 0.440121 Herbert V 0.324024 NCI Laetrile Review 0.334924 Paxinos J 0.340814 Med Chem 0.296011	CLICK HERE
16821	National Cancer Institute	Html	es	Essiac y Flor Essence (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de Essiac y Flor Essence como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Task Force 0.308376 Cancer Research Initiative 0.320196 unconventional cancer treatments 0.320494 herbal tonic does 0.3061 Flor Essence 0.978719 Emergency Drug Release 0.331684 Essiac ayuda 0.314934 Unconventional therapies 0.309084 Breast Cancer Research 0.358515 PDQ Essiac 0.31235 Drug Release Program 0.32265 cnicus benedictus l 0.304919 herbal compound essiac 0.312331 Instituto Nacional 0.31012 empresa distribuyera essiac 0.312801 Estados Unidos 0.307377 rheum palmatum l 0.305051 Canadian Breast Cancer 0.360067 National Health 0.322894 Canadian Department 0.324322 Herbal treatments 0.307114 Richardson MA 0.304856 Tamayo C 0.317352 peligro flor essence 0.306091 Health Protection Branch 0.310516	dietary flavonoid agents 0.304813 Altramed Health Products 0.311033 Government Printing Office 0.30949 biological activity 0.306113 Women's Health 0.305948 Antiproliferative activity 0.305396 Technology Assessment 0.305013 inhibit mammary tumor 0.304807 trifolium pratense l 0.304784 Canada's Cancer Nurse 0.308951 tonic does not 0.304787 Canada’s Emergency Drug 0.305978 Chinese medicinal herbs 0.308908 Cancer Res Treat 0.313562 National Cancer Institute 0.306146 Canada's Emergency Drug 0.305939 Alternative Therapies 0.325498 accessed april 0.328259 breast cancer 0.403359 Cancer Research Alliance 0.319782 Human Prescription Drugs 0.320102 hierbas flor essence 0.306693 in vitro 0.330256 flor-essence herbal tonic 0.336948	CLICK HERE
16839	National Cancer Institute	Html	en	Previous NCI Alliance Grantees	The NCI Alliance for Nanotechnology in Cancer has funded a multitude of research and training grants since 2005. Find here a list of all of these high impact projects.	cancer-related nanotechnology research 0.909204 initiative 0.300481 private organizations 0.515908 Focus 0.261214 National Cancer Institute 0.829641	clinical practice 0.510503 clinicians 0.293138 areas 0.260532 NCI Alliance 0.657758 major commitment 0.597371	CLICK HERE